Wall Street brokerages forecast that SUMMIT THERAPEU/S (NASDAQ:SMMT) will announce earnings per share (EPS) of ($0.23) for the current quarter, Zacks reports. Two analysts have made estimates for SUMMIT THERAPEU/S’s earnings. The lowest EPS estimate is ($0.31) and the highest is ($0.19). SUMMIT THERAPEU/S reported earnings of ($0.65) per share during the same quarter last year, which would indicate a positive year over year growth rate of 64.6%. The firm is expected to announce its next earnings results on Tuesday, December 10th.
According to Zacks, analysts expect that SUMMIT THERAPEU/S will report full-year earnings of ($0.83) per share for the current year, with EPS estimates ranging from ($0.92) to ($0.76). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.82) per share, with EPS estimates ranging from ($0.88) to ($0.74). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow SUMMIT THERAPEU/S.
SUMMIT THERAPEU/S (NASDAQ:SMMT) last issued its earnings results on Friday, October 11th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.08. SUMMIT THERAPEU/S had a negative net margin of 1,432.73% and a negative return on equity of 61.73%. The company had revenue of $0.15 million during the quarter, compared to the consensus estimate of $0.43 million.
NASDAQ:SMMT opened at $1.68 on Friday. The company has a quick ratio of 3.47, a current ratio of 3.47 and a debt-to-equity ratio of 0.01. The business’s 50-day simple moving average is $1.60 and its two-hundred day simple moving average is $1.47. The stock has a market cap of $53.89 million, a PE ratio of 2.00 and a beta of 1.19. SUMMIT THERAPEU/S has a 52 week low of $1.10 and a 52 week high of $2.46.
An institutional investor recently raised its position in SUMMIT THERAPEU/S stock. Morgan Stanley boosted its stake in shares of SUMMIT THERAPEU/S (NASDAQ:SMMT) by 7.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 244,201 shares of the company’s stock after acquiring an additional 16,245 shares during the period. Morgan Stanley owned 1.76% of SUMMIT THERAPEU/S worth $309,000 at the end of the most recent quarter. Institutional investors own 8.28% of the company’s stock.
SUMMIT THERAPEU/S Company Profile
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Read More: What is the NASDAQ Stock Market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SUMMIT THERAPEU/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SUMMIT THERAPEU/S and related companies with MarketBeat.com's FREE daily email newsletter.